Currently, only IL13Rα2-specific CAR T cells have been administered intracranially to treat adult glioblastoma.434,435 While there is much work still required to see long-term survival benefits for adults with glioblastoma, or more broadly malignant gliomas, research spanning tumour characterisation, pre-clinical validation and clinical trials highlights the strong potential that cellular therapy and combined immunotherapy should be implemented to treat this disease. This evidence concerns the gene IL13RA2 and glioblastoma.